Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911278 | 0.83 | VCAM1 (0.56) | LMNACYP1A2CA1CA2CA12 | |
| SCHEMBL14593012 | 0.82 | ALDH1A1 (0.67) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL6471721 | 0.81 | CA1 (0.72) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL30582428 | 0.80 | LMNA (0.65) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL940578 | 0.80 | LMNA (0.65) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL2913651 | 0.80 | CA12 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL868290 | 0.79 | LMNA (0.62) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL28740731 | 0.78 | ALDH1A1 (0.49) | CA1CA2CA12CA9CA14 | |
| SCHEMBL9879781 | 0.78 | LMNA (0.53) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL2896481 | 0.78 | ALDH1A1 (0.62) | LMNACYP1A2CYP3A4MAOACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| EP-1325920-B1 | N-SUBSTITUTED BENZOTHIOPHENESULFONAMIDE DERIVATIVES | TOA EIYO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7399781-B2 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7071220-B2 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20060116408-A1 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| CN-1245400-C | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD (JP) | 2006-03-15 | — | — | CN | disclosed |
| US-20030229126-A1 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. | 2003-12-11 | — | — | US | disclosed |
| CN-1458928-A | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD (JP) | 2003-11-26 | — | — | CN | disclosed |
| EP-1325920-A1 | N-SUBSTITUTED BENZOTHIOPHENESULFONAMIDE DERIVATIVES | TOA EIYO LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116408-A1 | N-substituted benzothiophenesulfonamide derivatives | ECE1, ECE2, CMA1 | LMNA 2757/4885CYP1A2 3621/4885CYP3A4 3905/4885 |
| US-20030229126-A1 | N-substituted benzothiophenesulfonamide derivatives | ECE1, ECE2, CMA1 | LMNA 2757/4885CYP1A2 3621/4885CYP3A4 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.